HER2-POSITIVE METASTATIC BREAST CANCER
Clinical trials for HER2-POSITIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug BBO-10203 enters first human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail of drugs aims to keep HER2+ breast cancer in check
Disease control Recruiting nowThis Phase 2 trial is testing whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can help keep advanced breast cancer from growing. It involves 57 women with HR+/HER2+ metastatic breast cancer whose disease has not worsened after initial treatment. The …
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for Hard-to-Treat breast cancer: Real-World study launches
Disease control Recruiting nowThis study follows about 300 women with HER2-positive breast cancer that has spread. They are getting a three-drug combination (tucatinib, capecitabine, trastuzumab) as part of their normal care. The goal is to see how well the treatment works and how safe it is in everyday medic…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Sponsor: Fondazione Oncotech • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
PET scan could predict best drug sequence for advanced breast cancer
Disease control Recruiting nowThis study tests whether a special PET scan (HER2-PET) can help doctors decide which drug to use next in people with advanced HER2-positive breast cancer whose cancer has stopped responding to the drug trastuzumab deruxtecan (T-DXd). About 87 participants will get the scan and be…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Smartwatch and app join fight against metastatic breast cancer
Disease control Recruiting nowThis study tests the drug trastuzumab deruxtecan (T-DXd) as a first treatment for people with HER2-positive breast cancer that has spread. About 300 participants will take the drug and use digital tools like a smartwatch and pulse oximeter to catch side effects early. The goal is…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug pair aims to shrink Hard-to-Treat breast tumors
Disease control Recruiting nowThis study is for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It tests two drugs together: tucatinib and Doxil. The goal is to see how well the combination shrinks tumors and to track any side effects. About 36 adults will take part.
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy aims to control advanced breast cancer after other treatments fail
Disease control Recruiting nowThis study tests whether adding a trastuzumab biosimilar (SB3) to the chemotherapy drug eribulin helps control advanced HER2-positive breast cancer better than eribulin alone. It includes 180 adults whose cancer has spread or cannot be removed and who have already tried at least …
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug cocktail targets Hard-to-Treat breast cancer spread to brain
Disease control Recruiting nowThis study tests a combination of two oral chemotherapy drugs (tucatinib and capecitabine) plus a targeted antibody given directly into the spinal fluid (trastuzumab) for people with HER2-positive breast cancer that has spread to the lining of the brain and spinal cord (leptomeni…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a better HER2 test predict who responds to targeted therapy?
Diagnosis Recruiting nowThis study is testing a new, more precise method to measure HER2 levels in leftover tumor tissue from people with HER2-low metastatic breast cancer. The goal is to see if this test can accurately tell who will respond to the drug T-Dxd. Researchers will enroll 200 participants an…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Brain scan surveillance trial launches for HER2+ breast cancer patients
Knowledge-focused Recruiting nowThis study looks at whether it's possible to routinely scan the brains of people with HER2-positive metastatic breast cancer to find cancer spread early. About 69 participants will get a baseline brain MRI, and if no brain tumors are found, they'll be randomly assigned to either …
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: NA • Sponsor: Royal College of Surgeons, Ireland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC